Trial Profile

A Phase 1b Study of LY2157299 in Combination With Gemcitabine in Patients With Advanced or Metastatic Unresectable Pancreatic Cancer (H9H-JE-JBAO)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Galunisertib (Primary) ; Gemcitabine
Indications Pancreatic cancer
Focus Adverse reactions
Sponsors Eli Lilly and Company

Most Recent Events

01 Jun 2017 Results assessing the safety, tolerability, efficacy and pharmacokinetics of galunisertib in combination with gemcitabine in patients with metastatic or locally advanced pancreatic cancer, published in the Cancer Chemotherapy and Pharmacology.
09 Feb 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
15 Dec 2015 Planned End Date changed from 1 Oct 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com